Hamilton Lane Advisors’s CytomX Therapeutics CTMX Stock Holding History

Hamilton Lane Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-19,898	Closed	-$147K	–	48
2019 Q3	$147K	Hold	19,898	–	–	0.06%	47
2019 Q2	$223K	Hold	19,898	–	–	0.11%	42
2019 Q1	$214K	Sell	19,898 -48,855	-71%	-$722K	0.11%	50
2018 Q4	$1.04M	Sell	68,753 -12,000	-15%	-$178K	0.91%	23
2018 Q3	$1K	Hold	80,753	–	–	0.41%	28
2018 Q2	$2K	Sell	80,753 -24,780	-23%	-$633K	1.82%	14
2018 Q1	$3K	Buy	105,533 +55,139	+109%	+$1.57M	2.38%	13
2017 Q4	$1.06M	Buy	50,394 +22,048	+78%	+$457K	0.55%	35
2017 Q3	$515K	Buy	+28,346	New	+$442K	0.35%	37
2017 Q2	–	Sell	-21,199	Closed	-$366K	–	53
2017 Q1	$366K	Buy	+21,199	New	+$279K	0.18%	54

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hamilton Lane Advisors's CTMX Position: Q4 2019 in Review

Hamilton Lane Advisors sold out of CytomX Therapeutics (CTMX) in Q4 2019, closing a stake of 19,898 shares — an estimated $147K sold.

Hamilton Lane Advisors first reported a position in CTMX in Q1 2017 and held it in 10 quarters. The position peaked at $1.06M in Q4 2017. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2019.

Hamilton Lane Advisors reported no remaining CytomX Therapeutics position as of Q4 2019 after selling out during the quarter.
Hamilton Lane Advisors sold 19,898 CytomX Therapeutics shares in Q4 2019, an estimated $147K.
Hamilton Lane Advisors first reported a position in CytomX Therapeutics in Q1 2017 and held it in 10 quarters.
Hamilton Lane Advisors's CytomX Therapeutics position peaked at $1.06M in Q4 2017.
119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2019.

Based on Hamilton Lane Advisors's 13F filing for Q4 2019, filed 31 Jan 2020.